(Total Views: 620)
Posted On: 05/11/2019 7:01:36 AM
Post# of 154777
I have a position in GALT.
Phase 2 trial of belapectin did not meet the endpoint in fibrosis, however it was shown to stop the development of esophageal varices. It was a surprise result but highly beneficial to any patient with late stage NASH (the mechanism of action is unknown at this point).
In pre-clinical trials for melanoma it was quite successful in tumor shrinkage.
Phase 2 trial of belapectin did not meet the endpoint in fibrosis, however it was shown to stop the development of esophageal varices. It was a surprise result but highly beneficial to any patient with late stage NASH (the mechanism of action is unknown at this point).
In pre-clinical trials for melanoma it was quite successful in tumor shrinkage.
(0)
(0)
